vs
Side-by-side financial comparison of NovaBay Pharmaceuticals, Inc. (NBY) and Virgin Galactic Holdings, Inc (SPCE). Click either name above to swap in a different company.
NovaBay Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($4.8M vs $4.2M, roughly 1.1× Virgin Galactic Holdings, Inc). NovaBay Pharmaceuticals, Inc. runs the higher net margin — -25.5% vs -2222.2%, a 2196.6% gap on every dollar of revenue. On growth, NovaBay Pharmaceuticals, Inc. posted the faster year-over-year revenue change (126.1% vs 125.5%). NovaBay Pharmaceuticals, Inc. produced more free cash flow last quarter ($-1.7M vs $-113.5M).
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
Virgin Galactic Holdings, Inc. is a British-American spaceflight company founded by Richard Branson and the Virgin Group conglomerate, which retains an 11.9% stake through Virgin Investments Limited.
NBY vs SPCE — Head-to-Head
Income Statement — Q4 FY2024 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $4.8M | $4.2M |
| Net Profit | $-1.2M | $-93.8M |
| Gross Margin | 65.2% | -546.6% |
| Operating Margin | -37.2% | -2412.1% |
| Net Margin | -25.5% | -2222.2% |
| Revenue YoY | 126.1% | 125.5% |
| Net Profit YoY | 70.5% | 30.2% |
| EPS (diluted) | — | $-4.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 24 | $4.8M | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $2.4M | $4.2M | ||
| Q1 24 | $2.6M | $2.0M | ||
| Q4 23 | $2.1M | $2.8M | ||
| Q3 23 | $2.5M | $1.7M | ||
| Q2 23 | $3.5M | $1.9M | ||
| Q1 23 | $2.3M | — |
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $-1.2M | — | ||
| Q2 24 | $-1.6M | $-93.8M | ||
| Q1 24 | $-3.2M | $-102.0M | ||
| Q4 23 | $-4.1M | $-104.0M | ||
| Q3 23 | $-1.8M | $-104.6M | ||
| Q2 23 | $-2.0M | $-134.4M | ||
| Q1 23 | $-1.7M | — |
| Q4 24 | 65.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 66.3% | -546.6% | ||
| Q1 24 | 68.2% | -1038.1% | ||
| Q4 23 | 51.5% | -766.4% | ||
| Q3 23 | 67.0% | -1384.3% | ||
| Q2 23 | 49.2% | 87.5% | ||
| Q1 23 | 68.4% | — |
| Q4 24 | -37.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -67.4% | -2412.1% | ||
| Q1 24 | -87.1% | -5599.9% | ||
| Q4 23 | -48.0% | -4067.8% | ||
| Q3 23 | -28.1% | -6613.0% | ||
| Q2 23 | -29.7% | -7459.4% | ||
| Q1 23 | -57.5% | — |
| Q4 24 | -25.5% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -66.0% | -2222.2% | ||
| Q1 24 | -122.2% | -5139.1% | ||
| Q4 23 | -195.5% | -3701.8% | ||
| Q3 23 | -70.8% | -6053.5% | ||
| Q2 23 | -57.6% | -7181.4% | ||
| Q1 23 | -74.3% | — |
| Q4 24 | — | — | ||
| Q3 24 | $-1.92 | — | ||
| Q2 24 | $-1.37 | $-4.36 | ||
| Q1 24 | $-29.95 | $-5.10 | ||
| Q4 23 | — | $-14.49 | ||
| Q3 23 | — | $-5.57 | ||
| Q2 23 | — | $-9.16 | ||
| Q1 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $430.0K | $775.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-129.0K | $394.8M |
| Total Assets | $3.4M | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 24 | $430.0K | — | ||
| Q3 24 | $776.0K | — | ||
| Q2 24 | $751.0K | $775.7M | ||
| Q1 24 | $1.8M | $765.2M | ||
| Q4 23 | $2.9M | $874.0M | ||
| Q3 23 | $3.5M | $997.1M | ||
| Q2 23 | $4.4M | $940.2M | ||
| Q1 23 | $3.7M | — |
| Q4 24 | $-129.0K | — | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $-617.0K | $394.8M | ||
| Q1 24 | $160.0K | $417.6M | ||
| Q4 23 | $3.3M | $505.5M | ||
| Q3 23 | $7.0M | $599.4M | ||
| Q2 23 | $8.6M | $484.5M | ||
| Q1 23 | $8.9M | — |
| Q4 24 | $3.4M | — | ||
| Q3 24 | $3.9M | — | ||
| Q2 24 | $3.9M | $1.1B | ||
| Q1 24 | $5.4M | $1.1B | ||
| Q4 23 | $9.0M | $1.2B | ||
| Q3 23 | $12.9M | $1.3B | ||
| Q2 23 | $16.0M | $1.1B | ||
| Q1 23 | $14.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-79.1M |
| Free Cash FlowOCF − Capex | $-1.7M | $-113.5M |
| FCF MarginFCF / Revenue | -35.4% | -2690.7% |
| Capex IntensityCapex / Revenue | 0.1% | 815.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-458.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $-2.4M | — | ||
| Q2 24 | $-1.4M | $-79.1M | ||
| Q1 24 | $-2.0M | $-113.2M | ||
| Q4 23 | $-592.0K | $-95.3M | ||
| Q3 23 | $-646.0K | $-91.5M | ||
| Q2 23 | $-1.7M | $-125.3M | ||
| Q1 23 | $-1.2M | — |
| Q4 24 | $-1.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-113.5M | ||
| Q1 24 | $-2.0M | $-126.3M | ||
| Q4 23 | $-595.0K | $-113.7M | ||
| Q3 23 | $-647.0K | $-104.8M | ||
| Q2 23 | $-1.7M | $-135.2M | ||
| Q1 23 | $-1.2M | — |
| Q4 24 | -35.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2690.7% | ||
| Q1 24 | -75.3% | -6362.8% | ||
| Q4 23 | -28.3% | -4046.9% | ||
| Q3 23 | -26.1% | -6066.1% | ||
| Q2 23 | -48.3% | -7224.3% | ||
| Q1 23 | -51.3% | — |
| Q4 24 | 0.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.0% | 815.5% | ||
| Q1 24 | 0.1% | 658.5% | ||
| Q4 23 | 0.1% | 653.9% | ||
| Q3 23 | 0.0% | 771.1% | ||
| Q2 23 | 0.1% | 526.4% | ||
| Q1 23 | 0.6% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NBY
| Other | $2.4M | 51% |
| Total Product Revenue | $2.3M | 49% |
SPCE
Segment breakdown not available.
